Join
Live feed
·
PRReleasevia Quantisnow
Xencor Inc. logo

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

ByQuantisnow·Wall Street's wire, on your screen.
XNCR· Xencor Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XNCR (Xencor Inc.) and more on Quantisnow.